Gameto Highlights ARPA-H–Backed Menopause Treatment Program Ahead of ASRM 2025

Gameto has shared an update.

The company announced that its R&D Chief of Staff, Alexander Noblett, PhD, will deliver a booth talk at ASRM 2025 titled “Reimagining Menopause Treatment with a Steroidogenic, Hormone-Sensitive Ovarian Implant.” The presentation will focus on Gameto’s Ameno program, which leverages engineered ovarian-like cells and controlled androgen release as a novel approach to menopause treatment. The company highlighted that the Ameno program received funding from the Advanced Research Projects Agency for Health’s (ARPA-H) Sprint for Women’s Health Initiative in fall 2024, and noted that Noblett will be available to discuss the research in further detail at the conference.

For investors, this update underscores Gameto’s progress in developing differentiated therapeutics in the women’s health space and validates its technology through non-dilutive ARPA-H funding. The ASRM 2025 exposure may enhance the company’s visibility among clinicians, researchers, and potential partners, which could support future collaboration or licensing opportunities. While the post does not provide clinical or commercial timelines, the focus on a hormone-sensitive implant for menopause addresses a large, underserved market, suggesting that successful advancement of the Ameno program could materially improve Gameto’s long-term revenue prospects and strengthen its position within the reproductive and women’s health biotechnology segment.